Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Health Canada is recalling compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy.

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

.Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.